Pfizer vs J&J: Pharma Ethics Head-to-Head
Pfizer more than doubled the price of Paxlovid from $530 to $1,390 per course during the pandemic, according to regulatory records. Johnson & Johnson was investigated by South Africa's Competition Commission for allegedly overcharging for bedaquiline, a tuberculosis drug, in a country with one of the highest TB rates in the world.
Both companies develop life-saving medicines. Both have accumulated billions of dollars in regulatory fines. And if you own a healthcare ETF or diversified portfolio, you almost certainly hold one or both of them.
Mashinii scores over 6,000 public companies across 11 ethical dimensions using independently sourced evidence -- penalty records, regulatory actions, verified reporting, and third-party audits. We compared Pfizer and Johnson & Johnson head-to-head on the dimensions that matter most for pharmaceutical companies, and benchmarked them against Merck and AbbVie.
The Scores: Head-to-Head
| Dimension | Pfizer | J&J | Merck | AbbVie |
|---|---|---|---|---|
| Better Health for All | -60 | -40 | +30 | +10 |
| Honest & Fair Business | -60 | -20 | 0 | 0 |
| Fair Pay & Worker Respect | +10 | +20 | +30 | +20 |
| Planet-Friendly Business | -40 | +10 | -30 | -30 |
| Kind to Animals | -10 | -30 | -30 | -20 |
| Respect for Cultures & Communities | -20 | +50 | +20 | +20 |
| Safe & Smart Tech | 0 | +10 | +20 | -20 |
| No War, No Weapons | -10 | -20 | 0 | -10 |
Scores range from -100 (worst) to +100 (best). Source: Mashinii integrity intelligence platform.
Johnson & Johnson outperforms Pfizer on most dimensions. But the 100-point gap between Merck (+30) and Pfizer (-60) on Better Health for All is the more striking finding. On the metric that should define a pharmaceutical company, the spread within the industry is enormous.
Drug Pricing: Paxlovid at $1,390 vs Bedaquiline Access Disputes
This value measures drug pricing practices, access to essential medicines, clinical trial transparency, and investment in underserved populations. It is the dimension that should define a pharmaceutical company. Both Pfizer and J&J score negative.
Pfizer (-60) carries several documented pricing actions. During the pandemic, Pfizer raised Paxlovid's price from $530 to $1,390 per course -- more than doubling the cost of a COVID-19 treatment while the virus was still killing thousands weekly. In April 2024, the company paid $25.5 million to settle antitrust claims for allegedly colluding to delay the generic version of Effexor XR. In late 2022, five Pfizer drugs had price increases that exceeded inflation.
Pfizer has launched access programmes. Its "Accord for a Healthier World" aims to provide medicines at cost to 45 countries. But as of September 2024, only ten countries are participating due to bureaucratic and infrastructural barriers. Its Multicultural Health Equity Collective has reached 1.5 million individuals in marginalised U.S. communities since 2014.
Johnson & Johnson (-40) faces its own pricing record. South Africa's Competition Commission investigated J&J for allegedly charging excessive prices for bedaquiline -- a tuberculosis drug -- in a country where TB is a leading cause of death. J&J also implemented a rebate model in the U.S. 340B Drug Pricing Programme that critics argue undermines affordable access for safety-net providers.
On the positive side, J&J invested $25 million, matched by the Global Fund, in the Africa Frontline First Catalytic Fund, aimed at tripling salaried community health workers in 12 African countries. The company supports over 100 grassroots health organisations across the U.S.
Drug Pricing Side-by-Side
| Pfizer | Johnson & Johnson | |
|---|---|---|
| Documented price hike | Paxlovid: $530 to $1,390 per course (Oct 2023) | Bedaquiline: investigated for excessive pricing in South Africa |
| Additional pricing concerns | 5 drugs with above-inflation increases (late 2022); $25.5M antitrust settlement for delaying Effexor XR generic | 340B rebate model criticised for undermining safety-net pricing |
| Access programme reach | "Accord for a Healthier World" -- 10 of 45 targeted countries participating | Africa Frontline First Fund -- $50M (with Global Fund match) for 12 countries |
| Patient assistance | Multicultural Health Equity Collective -- 1.5M individuals since 2014 | 100+ community health organisations supported across U.S. |
For context, Merck scores +30 on this dimension, with voluntary licensing in 100+ countries and a pipeline addressing 83% of the top 20 global disease burdens. The gap between Merck and Pfizer on the metric that should define pharma is 90 points.
Pfizer's $60M Kickback Settlement vs J&J's $700M Talc Verdict
Pfizer (-60) was fined 63 million pounds by the UK Competition and Markets Authority in 2022 for increasing the price of an epilepsy drug. In January 2025, the company agreed to pay nearly $60 million to settle allegations of kickbacks to healthcare providers for prescribing Nurtec ODT, leading to false claims under federal healthcare programmes. That totals approximately $138.75 million in fines and settlements within three years.
A former Pfizer compliance officer filed a lawsuit in August 2023 alleging retaliation after reporting potential Foreign Corrupt Practices Act violations related to excessive payments to officials in China. According to court records, this raises questions not about the existence of compliance mechanisms but about whether those mechanisms protect the people who use them.
Johnson & Johnson (-20) has incurred over $1 billion in ethics-related regulatory penalties in the past three years, according to regulatory filings. The largest was a $700 million multi-agency settlement for consumer protection violations related to talc product marketing. A $302 million penalty from the California Attorney General in 2023 addressed drug and medical equipment safety violations. And a $9.75 million False Claims Act settlement with the DOJ rounded out the tally.
Despite larger absolute penalty totals, J&J scores less negative than Pfizer. The company maintains a 100% third-party intermediary due diligence programme for anti-corruption, annual risk assessments across all subsidiaries, and participation in the Transparency International UK Corporate Anti-Corruption Benchmark. According to its filings, 100% of regulatory inspections by worldwide health authorities did not result in a classification, and zero FDA warning letters were issued.
Clinical Trial Transparency and Patient Safety
Both companies develop medicines that millions depend on. Their records on transparency differ.
Pfizer's clinical trial registry shows a large volume of registered studies, but the Effexor XR antitrust case ($25.5M settlement) specifically involved alleged efforts to delay generic competition -- an action that directly affects patient access to affordable treatment. The former compliance officer's lawsuit alleging retaliation for reporting FCPA violations in China raises separate questions about internal reporting culture.
J&J's record includes a $302 million penalty from the California Attorney General in 2023 for drug and medical equipment safety violations. But the company reports that 100% of regulatory inspections by worldwide health authorities did not result in a classification in the most recent period, and zero FDA warning letters were issued. Its 100% third-party intermediary due diligence programme for anti-corruption provides structural oversight that Pfizer's compliance record -- with an active whistleblower retaliation lawsuit -- does not match.
Which Pharma Company Treats Workers Better?
Both companies score positively on worker treatment, though J&J leads.
J&J (+20) reports a CEO-to-median employee pay ratio of 75:1. The company has an overall employee rating of 4.1 out of 5 stars based on over 13,000 reviews, with 81% recommending it as a workplace. In 2023, 91% of employees agreed the company maintains clean and safe working conditions.
Pfizer (+10) settled a gender-based compensation discrimination case in 2023, paying $2 million after the U.S. Department of Labor found violations affecting 86 female employees at its New York headquarters. Pfizer's 2025 pay equity study found females globally compensated at 99.5% of male colleagues in comparable roles and U.S. minorities at 100% parity. However, the overall median pay for U.S. minorities is 83.9% of non-minorities, indicating a representation gap in senior roles.
Merck again leads the peer group at +30, with over 99% pay equity worldwide and recognition as one of Fortune's 100 Best Companies to Work For.
Community Engagement and Environmental Performance
The largest single-dimension gap between the two companies is on Respect for Cultures & Communities: J&J scores +50, Pfizer scores -20. A 70-point spread.
J&J collaborates with over 100 community-led health organisations across the U.S. to advance health equity. The Africa Frontline First Catalytic Fund represents a significant commitment to community health infrastructure.
Pfizer's community score reflects a documented history. A 1996 clinical trial in Kano, Nigeria during a meningitis epidemic led to allegations of improper informed consent and a $75 million settlement in 2009. Records also show a partner's CEO made comments in 2001 implying no need to share benefits with the San people, though Pfizer later withdrew from the project.
On Planet-Friendly Business, J&J is the only company in this comparison to score positively (+10). Its global electricity is 87% renewable, with a 23% reduction in Scope 1 and 2 emissions between 2021 and 2023. Pfizer scores -40, with total emissions of 4.63 million tCO2e in 2024 and only 14.4% renewable energy.
Patient Access: A Summary
The pharmaceutical industry's core promise is that its products reach the people who need them. On this measure, the data tells a clear story.
Pfizer's access record: Paxlovid priced at $1,390 per course. Five drugs with above-inflation increases in a single year. An antitrust settlement for delaying a generic. Its flagship access programme has enrolled 10 of 45 target countries after two years.
J&J's access record: Bedaquiline pricing investigated in South Africa -- a country where TB kills tens of thousands annually. A 340B rebate model that critics say undermines safety-net providers. But also a $50 million fund (with the Global Fund) for community health workers in 12 African countries.
The benchmark: Merck scores +30 with voluntary licensing in 100+ countries, HPV vaccines at access prices, and 33,000 health workers trained through Project ECHO.
Pfizer vs Johnson & Johnson: Which Pharma Company Is More Ethical?
Neither Pfizer nor Johnson & Johnson scores positively on the two dimensions that should define a pharmaceutical company -- health access and corporate integrity.
J&J outperforms Pfizer on governance (-20 vs -60), health access (-40 vs -60), environment (+10 vs -40), and community engagement (+50 vs -20). Pfizer's lower scores concentrate in the areas most relevant to its own industry.
For investors comparing pharma holdings, Merck scores highest among major players, with positive marks in health access (+30), worker treatment (+30), and technology responsibility (+20).
For the full healthcare sector ranking, see our analysis of the most ethical healthcare companies in 2026. For a different sector entirely, see how defence stocks score on ethics.
How We Score
Every score in this analysis is derived from penalty records, court outcomes, regulatory filings, and verified third-party reporting. No corporate self-assessments. Learn more about our methodology.
For Financial Advisors
Clients asking about pharma holdings? Mashinii provides source-cited integrity data for Consumer Duty suitability evidence. Explore the advisor solution.
Audit My Portfolio | Search Any Company | View Rankings
Mashinii provides integrity data for informational purposes. This is not financial advice.